Morgan Stanley downgraded Neurocrine (NBIX) to Equal Weight from Overweight with a price target of $175, up from $173. The firm sees Neurocrine facing several potential headwinds over the coming year and with limited clinical catalysts until 2027, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data
- Neurocrine Biosciences: Ingrezza-Driven Strength and Risk-Balanced Pipeline Support Buy Rating Despite Valbenazine Setback
- Buy Rating Reaffirmed on Neurocrine: Limited Impact from Trial Setback, Strength in Core Execution and Deep Pipeline Upside
- Neurocrine says Phase 3 KINECT-DCP study of valbenazine did not meet endpoints
- Neurocrine Biosciences Launches Phase 2 Trial for Bipolar I Disorder Treatment